Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.475 USD | +15.42% | +19.44% | -27.20% |
05:15pm | JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating | MT |
May. 10 | Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
- Stock Market
- Equities
- PRME Stock
- News Prime Medicine, Inc.
- MarketScreener Editorial Features